Literature DB >> 22612072

Adeno-associated virus-mediated gene delivery of the human ND4 complex I subunit in rabbit eyes.

Hui Shi1, Jing Gao, Han Pei, Rong Liu, Wei-kun Hu, Xin Wan, Tao Li, Bin Li.   

Abstract

BACKGROUND: To assess intravitreal injection dose and safety of recombinant adeno-associated virus-mediated gene delivery of human NADH dehydrogenase subunit 4 (ND4) in rabbit eyes.
METHODS: An open reading frame for human ND4 or adeno-associated virus-green fluorescent protein were fused to the mitochondrial targeting sequence and packed into separate adeno-associated virus capsids. Rabbits of three treatment groups were administered 0.1 mL adeno-associated virus-ND4, 0.1 mL adeno-associated virus-green fluorescent protein or 0.1 mL vehicle via intravitreal injection, respectively. The safety of recombinant adenoassociated virus-mediated gene delivery of human ND4 in rabbit eyes was assessed with a slit-lamp microscope and direct ophthalmoscope, measurements of intraocular pressure and flash visual evoked potential, and optical coherence tomography. The mRNA and protein expressions of human ND4 in the retina of rabbits were determined with real-time polymer chain reaction (PCR), immunofluorescence and Western blot.
RESULTS: No complications occurred in any of the three treatment groups after the intravitreal injection. At 1-month post-injection, no significant difference in the mean thickness of retinal nerve fibre layer was found among the three groups. Results of the visual evoked potential test showed that there was no difference in the latency of the visual P100 wave among the three groups. Real-time PCR, immunofluorescence and Western blot analyses verified the expressions of ND4 and green fluorescent protein in the retinal nerve fibre layer.
CONCLUSIONS: Intravitreal injection of adeno-associated virus-ND4 expression vectors was effectively and safely performed in our study. The data on the dose and method of intravitreal injection from our study will provide a valuable reference for clinical intravitreal injection of adeno-associated virus-ND4 for the treatment of Leber's hereditary optic neuropathy.
© 2012 The Authors. Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22612072     DOI: 10.1111/j.1442-9071.2012.02815.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  8 in total

Review 1.  Emerging aspects of treatment in mitochondrial disorders.

Authors:  Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2015-05-12       Impact factor: 4.982

2.  Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.

Authors:  Xing Wan; Han Pei; Min-jian Zhao; Shuo Yang; Wei-kun Hu; Heng He; Si-qi Ma; Ge Zhang; Xiao-yan Dong; Chen Chen; Dao-wen Wang; Bin Li
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

3.  Evaluation of Leber's hereditary optic neuropathy patients prior to a gene therapy clinical trial.

Authors:  Shuo Yang; Hong Yang; Si-Qi Ma; Shuai-Shuai Wang; Heng He; Min-Jian Zhao; Bin Li
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 4.  The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy.

Authors:  Yong Zhang; Zhen Tian; Jiajia Yuan; Chang Liu; Hong Li Liu; Si Qi Ma; Bin Li
Journal:  Curr Gene Ther       Date:  2017       Impact factor: 4.391

5.  Peripapillary Intravitreal Injection Improves AAV-Mediated Retinal Transduction.

Authors:  Sanjar Batirovich Madrakhimov; Jin Young Yang; Dong Hyuck Ahn; Jung Woo Han; Tae Ho Ha; Tae Kwann Park
Journal:  Mol Ther Methods Clin Dev       Date:  2020-03-30       Impact factor: 6.698

6.  Prognostic factors for visual acuity in patients with Leber's hereditary optic neuropathy after rAAV2-ND4 gene therapy.

Authors:  Yong Zhang; Xin Li; Jiajia Yuan; Zhen Tian; Hongli Liu; Dan Wang; Bin Li
Journal:  Clin Exp Ophthalmol       Date:  2019-05-08       Impact factor: 4.207

7.  Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.

Authors:  Shuo Yang; Si-Qi Ma; Xing Wan; Heng He; Han Pei; Min-Jian Zhao; Chen Chen; Dao-Wen Wang; Xiao-Yan Dong; Jia-Jia Yuan; Bin Li
Journal:  EBioMedicine       Date:  2016-07-06       Impact factor: 8.143

8.  A retrospective analysis of characteristics of visual field damage in patients with Leber's hereditary optic neuropathy.

Authors:  Ruijin Ran; Shuo Yang; Heng He; Shiqi Ma; Zhiqi Chen; Bin Li
Journal:  Springerplus       Date:  2016-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.